




National Institute of
Environmental Health Sciences
Division of Translational Toxicology



NAMs Activities at NIEHS/DTT and NICEATM

Nicole C. Kleinstreuer, PhD

**Director, NTP Interagency Center for the Evaluation of
Alternative Toxicological Methods**

National Institutes of Health • U.S. Department of Health and Human Services

Exposure-based Research Programs




Health Effects Innovation Programs




Responsive Research Programs



Strengthening Capabilities Programs



Developmental Neurotoxicity (DNT) Health Effect Innovation (HEI) Program



Stakeholder nominated chemical library

Selection Criteria


- Evidence of DNT *in vivo*
- Known human exposure
- Guideline study complete, lacking *in vitro*
- Suggested by multiple stakeholders
- Incomplete *in vitro* battery data

Phase I: 115 chemicals


- Testing finalized by contractors
- Data analyses finalized
- Manuscript in preparation

Phase II: ~100 chemicals


- Chemicals have been sent to contractors for testing





Environmental Exposures and Disease





Translational Human Research in Cancer




Systematic Evidence Mapping and Computational Modeling for CV Risk



Integrating HTS assay data and exposure




Identification of CV-relevant targets and endpoints



QSAR models for CardioToxPi mechanistic target groupings

Combined Exposures and Mixtures Program


Support for the Botanical Safety Consortium: A public-private partnership aiming to evaluate the suitability of NAM-based toxicity assays for use with complex mixture botanical ingredients




- The OIE Program aims to expand capabilities for predicting adverse health effects
- Currently evaluating novel/alternative technologies (i.e., in vitro models and microphysiological systems) to investigate human-relevant inhalation (respiratory) toxicity
 - Screening level assessments to predict toxicity, guide additional study design, mechanistic evaluations of MoAs/AOPs

In vitro air-liquid interface (ALI) airway cultures with Vitrocell 48 2.0 plus exposure system

Exposure to vapors, gases,
aerosols, or particles
(↑ doses & throughput)



www.vitrocell.com



www.atcc.org

Human-derived primary airway cells
from tracheobronchial, bronchial, or
alveolar compartment (testing of
multiple donors and rodent cells also
possible)

Proof-of-concept (pilot) study in-progress testing 2,3-pentanedione vapors (Q3/2023)



- **Clustering and classification workshop:**

- Convened international experts to discuss methods, their applications guide toxicology research and inform hazard and risk assessment.

- **Accomplishments:**

- Defined the similarity concept for supervised and unsupervised approaches
- Introduced different approaches, corrected misconceptions
- Involved both NAM developers and users
- Established a consortium and a community for increasing communication and collaboration across sectors
- *Ongoing and future:* develop and share new ideas/concepts (best practices & innovation)

- **Systematic Evidence Mapping:**

- Established evidence-base to inform and direct class-based health-effect evaluations

- **Key projects:**

- Health effects of OFRs
- Personal care products and (1) early puberty and (2) fetal growth
- Resource for researchers and regulators to search, sort, filter published studies

Applications to Investigate Adverse Effects of Chemicals on
Human Health and Environment Workshop
October 3-4, 2022 • 8:30 a.m. – 4:00 p.m. EDT



...to be continued

<https://www.niehs.nih.gov/news/events/nams2022/index.cfm>




Getting to FAIR+ requires standard metadata, terminologies, and quality curation



Findable Magnifying glass icon	Persistent Identifiers (PIDs) ID icon	Rich metadata Checkmark icon	Indexed data repositories Checkmark icon	PIDs in metadata ID icon
Accessible Hand pointing icon	Standard communications protocol Checkmark icon	Open, free protocol Dollar sign icon	Authentication, where necessary User icon	Metadata is always available Checkmark icon
Interoperable Gears icon	Vocabularies Checkmark icon	Vocabularies are FAIR Checkmark icon	Linked metadata Checkmark icon	
Reusable Recycling icon	Metadata have multiple attributes Checkmark icon	Usage license Checkmark icon	Provenance Checkmark icon	Community standards Checkmark icon

- Establishment of a DTT Data Dictionary
 - e.g., populations, treatments, outcomes, endpoints
 - Incorporated into DSMPs
 - In-house expertise with ontologies
- Community is key, both local and global:
 - DTT Knowledge Management Team
 - DTT-EPA collaborations
 - Engagement with ontology communities, e.g.
 - Ontology for Biomedical Investigations (OBI)
 - Adverse Outcome Pathways (AOPs)
 - Engagement with NIEHS grantee communities
 - Environmental Health Language Collaborative

NIH Office of Data Science Strategy FAIR checklist




EHLC Mission: to advance integrative environmental health research by promoting access, use, and harmonization of data through interoperable terminologies and best practices.

Use Case	Champion
1. What data exists for a given chemical/endpoint/exposure scenario?	Michelle Angrish, EPA Shannon Bell, RTI
2. What are the biological processes and biomarkers associated with exposure and how do they relate to the potential for an adverse outcome associated with a given exposure	Steve Edwards, RTI Chirag Patel, Harvard University
3. How do we combine individual-level data from multiple independent studies to understand how exposures X+Y impact health outcome Z?	Jeanette Stingone, Columbia University

Contact: Stephanie Holmgren (Holmgren@niehs.nih.gov)

- Integrated Chemical Environment
- OPERA (QSAR/QSPR)
- Computational Chemistry
- Quantitative IVIVE
- Reference data curation
- Variability of in vivo data
- Acute Systemic Toxicity
- Dermal absorption
- Eye and skin irritation
- Skin sensitization
- Ecotoxicology
- Carcinogenesis
- Cardiovascular Toxicity
- Developmental Toxicity
- DNT Testing Battery
- Zebrafish models
- Animal-free affinity reagents
- Microphysiological Systems
- Evolving Process of Validation




<https://ntp.niehs.nih.gov/go/2021iccvamreport>



Subscribe to NICEATM News email list
<https://ntp.niehs.nih.gov/go/niceatm>



(Q)SAR
=
(Quantitative) Structure-Activity Relationship



IN SILICO






- 35 Groups: academia, industry, govt
- Curate reference data to train & test models: >10k chemicals
- Use molecular structure and chemical properties to predict toxicity (e.g. endocrine disruption, acute systemic effects)
- Combine best models together into “ensemble” approaches
- Create open access AI/ML modeling suite



[https://github.com/
NIEHS/OPERA](https://github.com/NIEHS/OPERA)



<https://ice.ntp.niehs.nih.gov/>



Collaborative Acute Toxicity Modeling Suite (CATMoS) Performance

	Very Toxic		Non-Toxic		EPA		GHS	
	Train	Eval	Train	Eval	Train	Eval	Train	Eval
Sensitivity	0.87	0.70	0.88	0.67	0.81	0.62	0.80	0.58
Specificity	0.99	0.97	0.97	0.90	0.92	0.86	0.95	0.90
Balanced Accuracy	0.93	0.84	0.92	0.78	0.87	0.74	0.88	0.74
<i>In vivo</i> Balanced Accuracy	0.81		0.89		0.82		0.79	

	LD50 values		LD50 values
	Train	Eval	<i>In Vivo</i>
R2	0.85	0.65	0.80
RMSE	0.30	0.49	0.42


CATMoS QSAR predictions perform just as well as replicate *in vivo* data at predicting oral acute toxicity outcome

Karmaus et al. Toxicol Sci. 2022; Mansouri et al. EHP 2021

Analyzing sources of variability in acute oral toxicity data & quantifying 95% confidence interval

Inventory Sources and Summary

- **ECHA REACH Database**
 - Data Rows: 3016
 - Unique Substances: 611
- **ChemIDplus**
 - Data Rows: 2036
 - Unique Substances: 1249
- **Department of Defense**
 - Reports: 22
 - Unique Substances: 13
- **EPA AEGL**
 - Data Rows: 1682
 - Unique Substances: 271
- **NIOSH Pocket Guide**
 - Data Rows: 136
 - Unique Substances: 649




*GHS, EPA OPP, EPA OPPT, CPSC, etc.

Total # Unique Chemicals

- in database: **1025**
- point estimate data: **780**
- limit data: **312**
- range data: **45**




Access the DASS App
<https://ntp.niehs.nih.gov/go/952311>



Chemical Name	SMILES	EC50	hCLAT	DPRA	ADRA	Metabolism Prediction	Electrophilic Substances	KeratinoSens	LuSens	TG422C	TG442E	TG442D	LLNA	GPMT
1,2-Dichloroethane	ClCCl	0.0001	1	1	1	1	1	1	1	1	1	1	1	1
1,2-Dibromoethane	BrCCBr	0.0001	1	1	1	1	1	1	1	1	1	1	1	1
1,2-Dichloroethane	ClCCl	0.0001	1	1	1	1	1	1	1	1	1	1	1	1
1,2-Dibromoethane	BrCCBr	0.0001	1	1	1	1	1	1	1	1	1	1	1	1
1,2-Dichloroethane	ClCCl	0.0001	1	1	1	1	1	1	1	1	1	1	1	1
1,2-Dibromoethane	BrCCBr	0.0001	1	1	1	1	1	1	1	1	1	1	1	1
1,2-Dichloroethane	ClCCl	0.0001	1	1	1	1	1	1	1	1	1	1	1	1
1,2-Dibromoethane	BrCCBr	0.0001	1	1	1	1	1	1	1	1	1	1	1	1
1,2-Dichloroethane	ClCCl	0.0001	1	1	1	1	1	1	1	1	1	1	1	1
1,2-Dibromoethane	BrCCBr	0.0001	1	1	1	1	1	1	1	1	1	1	1	1

Color-coded results table
Yellow: User selected data columns
Pink: Translated user data, input for DASS algorithms
Blue: DASS predictions




DPRA Mean (Calculated)	dpra_pK	DPRA %K Depletion Input	DA ITS h-CLAT Score	DA ITS DPRA Score	DA ITS in Silico Score	DA ITS Total Score	DA ITS Call	DA ITS Potency	DA 203 Call	DA KE 3/4 STS Call	DA KE 3/4 STS Potency
50.75	3.6	3.6	2	3	1	6	1	1A	1	1	1B
0.3	0.6	0.6	2	0	NA	2	1	1B	1	1	1B
12.45	8.5	8.5	2	1	0	3	1	1B	1	1	1B
NA	<1	NA	3	2	1	6	1	1A	1	1	1A
51.85	28.4	28.4	3	3	1	7	1	1A	1	1	1A
0.9	1.8	1.8	0	0	0	0	0	NC	0	0	NC
45.85	11.5	11.5	2	3	NA	5	1	Inconclusive	1	1	1B
92.25	89.7	89.7	3	3	0	6	1	1A	1	1	1A
3.55	0.3	0.3	1	0	NA	1	Inconclusive	Inconclusive	0	1	1B
41.15	68.2	68.2	0	2	0	2	1	1B	0	0	NC

Values calculated by the app are shown to help the user understand derivation of predictions.

Translated input shows how the app interprets flagged data.

Individual and combined scores from the ITS are provided.

- Developed by Unilever as a defined approach for skin allergy risk assessment, expanded using data from OECD DASS project and beyond.
- A Bayesian statistical model which infers a human-relevant metric of sensitiser potency (termed ED_{01}), the dose with a 1% chance of human skin sensitisation.
- Accounts for variability of the input data and explicitly quantifies uncertainty.
- Utilises any combination of human repeat insult patch test (HRIPT), LLNA, direct peptide reactivity assay (DPRA), KeratinoSens™, h-CLAT, U-SENS™ data.
- The SARA-ICE Model was designed to be used within an NGRA Framework for decision making.
- On OECD workplan for TG497 evaluation.



Identification



Extraction



Annotation




Table location detection

Table structure prediction

(a) Row detection, no ruling lines present (b) Column detection, no ruling lines present

Postprocessing

Caption: Table 1. Profiles of experimental ...

Experimental group	N	Age (days)	...
Saline control	15	55 ± 4	...
0.1 mg TiO ₂	5	50 ± 1	...
0.1 mg ROFA	4	52 ± 1	...
...	3

Notes: N, number of rats. Values are mean ...

Age Weight Mean Arterial Pressure Experimental Group N (days) (g) ...
Saline control 15 55 ± 4 129 ± 4 ...
0.1 mg TiO₂ 5 50 ± 1 127 ± 9 ...

OLPR, ODS, ORNL

Text extraction

Primary Source Extraction Effects

Example:

Fetuses with small eyes

UMLS Vocabulary

Example:

UMLS:C0000768;CUI;Congenital Abnormality|
UMLS:C0015392;CUI;Eye|Eye|
UMLS:C0000846;CUI;Agnesis|Small agnesis|
UMLS:C0015392;CUI;Eye|Eye|
UMLS:C4086369;CUI;Gross Pathology Result|
UMLS:C0392756;CUI;Reduced|
UMLS:C0456389;CUI;size|
UMLS:C0000768;CUI;Congenital Abnormality|
UMLS:C0015392;CUI;Eye|Eye|
UMLS:C0023317;CUI;Lens, Crystalline|
UMLS:C0700321;CUI;Small|

User-Defined Look-Up Lists:

- Localizations
 - Observations
 - Combo Words
 - Unique Words
- Example:
- Localizations
 - Observations
 - Combo Words
 - Unique Words
 - ...

UMLS code mapping

DevTox


Example:

3.1032.5211
Viscera|Eye|Small
3.1161.5211
Viscera|Lens|
Small

OECD 74


Example:





074.186.66
Fetuses|Fetal abnormalities|
External|eye




- Important for leveraging high-quality studies in the published literature
- Applications in systematic review of chemical effects
- Establishing reference datasets for validating new methods

Using New Approach Methodologies to Address Variability and Susceptibility Across Populations







Covering Phase I CYP450 and Phase II UGTs enzymes




PBPK models + virtual population





<https://ice.ntp.niehs.nih.gov/>

Pharmacokinetic data on compounds metabolised by UGT isoforms is collected and summarised in a database



Interindividual differences in kinetics and polymorphisms



UGT-related uncertainty factors

Data on polymorphism frequencies in different populations is collected and summarised



Courtesy of Jean-Lou Dorne European Food Safety Authority

Incorporating Population Variability in Metabolism


Inputs needed:

1. Exposure (dose)
2. PBPK parameters
3. Enzyme variability data
4. Metabolite data
 - A. Structure
 - B. % Yield
 - C. Enzyme contribution



Model Parameters 



Parent Chemical



PBPK model:
ADME









Genetic variability




Metabolite 1

Metabolite 2

Metabolite 3



Linking in vitro HTS data and exposure information to predict geospatial risk of molecular perturbation.



Eventual goal: use approach to predict chemical contributions to adverse health outcomes across human populations





TOXICOLOGICAL SCIENCES, 2019, 1–16

doi: 10.1093/toxsci/afz238
Advanced Access Publication Date: December 6, 2019
Research Article

Development of an *In Vitro* Human Thyroid Microtissue Model for Chemical Screening

Chad Deisenroth ¹, Valerie Y. Soldatow,† Jermaine Ford,‡ Wendy Stewart,* Cassandra Brinkman,* Edward L. LeCluyse,† Denise K. MacMillan,‡ and Russell S. Thomas ¹*



Team Members

Coordinator: NICEATM

Method Developer

Lab 1

Lab 4



Lab 2



LifeNet Health®
Saving Lives. Restoring Health. Giving Hope.

Lab 3




CORTEVA™
agriscience

Status:

- Materials Cooperative Research and Development Agreement (MCRADA) in place
- Validation Management Team (VMT) recruited
- SOPs reviewed by VMT
- Transferability to lab 2 to start shortly



Microphysiological Systems for COVID-19 Research



Joint working group to support global COVID-19 tissue chip research activities
Partnership with NC3Rs, DoD, NIAID, NCATS, others.

<https://ntp.niehs.nih.gov/go/mps>

Kleinstreuer & Holmes (2021) Drug Discovery Today



Advancing Research and Regulatory Acceptance of Microphysiological Systems for Infectious Disease Applications
May 31 – June 1, 2023


- Understand pathophysiology and disease mechanisms
- Test novel therapeutics in tissue chip & MPS models and compare with pre/clinical data

<https://mps.csb.pitt.edu/>

<https://ntp.niehs.nih.gov/go/mps-2023wksp>

An in-person workshop to examine the state of the science for NAMs modeling the gastrointestinal tract and their context for regulatory consideration.

- **Focal Areas:**
 - General “state of the science” for NAM gut models
 - Models for de-risking chemicals for systemic toxicity (regulatory relevance and application)
 - Gastrointestinal toxicity
 - Systemic absorption and distribution
 - Gut allergenicity
- **A webinar series to provide background information is planned for September (dates TBD)**
- **In-person Day 1:** Scientific talks/state of the science
- **In-person Day 2:** Breakout groups covering the following themes:
 - Establishing confidence in existing models
 - Strengths and limitations of different model systems




The NICEATM Group

NIEHS/DTT Contributors



[https://ntp.niehs.nih.gov/go/
2021iccvamreport](https://ntp.niehs.nih.gov/go/2021iccvamreport)



Subscribe to NICEATM News
<https://ntp.niehs.nih.gov/go/niceatm>

